Skip to main content

Day: December 9, 2025

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) in MBC across all Phase III trials2-12New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13Basel, December 9, 2025 – Novartis today announced results showing that one in four patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) remained progression-free for four or more years following treatment with Kisqali® (ribociclib) plus endocrine therapy (ET)1. Results were from a pooled, post-hoc exploratory analysis of first-line patients in the MONALEESA trials and will be presented...

Continue reading

Heineken® 0.0 x LÕK serve up the world’s first padel racket with a built-in bottle opener

Heineken® 0.0 and premium racket brand LÕK announce the first-ever padel racket with a built-in bottle opener and six-pack branded balls.Heineken® 0.0 x LÕK serve up the world’s first padel racket with a built-in bottle openerHeineken® 0.0 and premium racket brand LÕK announce the first-ever padel racket with a built-in bottle opener and six-pack branded balls.Heineken® 0.0 x LÕK serve up the world’s first padel racket with a built-in bottle openerHeineken® 0.0 and premium racket brand LÕK announce the first-ever padel racket with a built-in bottle opener and six-pack branded balls The launch adds to Heineken® 0.0’s expanding presence in padel, adding to its new global partnerships with Playtomic and Premier PadelAMSTERDAM, Dec. 09, 2025 (GLOBE NEWSWIRE) — Heineken® 0.0 and LÕK today announce the Special...

Continue reading

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today released a year-end Letter from Chief Executive Officer Jody Aufrichtig, summarizing the Company’s 2025 achievements and outlining its strategic vision for 2026. In his year-end letter to shareholders, Aufrichtig described 2025 as a “turning point” in which Psyence BioMed delivered clinical execution, strengthened global manufacturing ties, and positioned itself at the forefront of the convergence between nature-derived psychedelic therapeutics and longevity science. “We recruited and dosed our first patients in a Phase IIb study. Through a further investment in PsyLabs we secured our psychedelic...

Continue reading

Gencor Releases Fourth Quarter and Fiscal Year 2025 Results

ORLANDO, Fla., Dec. 09, 2025 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the fourth quarter ended September 30, 2025 of $18.8 million, down 10.0% from $20.9 million net revenue for the quarter ended September 30, 2024. Gross profit as a percentage of net revenue was 24.2% for the quarter ended September 30, 2025, compared to 25.6% for the quarter ended September 30, 2024. The lower gross profit margin in fiscal 2025 was due to reduced manufacturing overhead absorption. Operating loss for the quarter ended September 30, 2025 was ($0.2) million compared to operating income of $1.2 million for the quarter ended September 30, 2024 due to lower gross profit margins and higher selling, general and administrative (“SG&A”) expenses. The Company had net...

Continue reading

SailPoint Announces Fiscal Third Quarter 2026 Results

AUSTIN, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) — SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, today announced financial results for its fiscal third quarter ended October 31, 2025. The company’s earnings release and presentation can be accessed on the quarterly results section of SailPoint’s investor relations website. SailPoint will host a conference call today at 8:30 a.m. Eastern Time to discuss the results and outlook, which is accessible here. About SailPoint At SailPoint (Nasdaq: SAIL), we believe enterprise security must start with identity at the foundation. Today’s enterprise runs on a diverse workforce of not just human but also digital identities—and securing them all is critical. Through the lens of identity, SailPoint empowers organizations to seamlessly manage and secure access to applications...

Continue reading

AutoZone 1st Quarter Total Company Same Store Sales Increase 4.7%; Domestic Same Store Sales Increase 4.8%; 1st Quarter EPS of $31.04

MEMPHIS, Tenn., Dec. 09, 2025 (GLOBE NEWSWIRE) — AutoZone, Inc. (NYSE: AZO) today reported net sales of $4.6 billion for its first quarter (12 weeks) ended November 22, 2025, an increase of 8.2% from the first quarter of fiscal 2025 (12 weeks). Same store sales, or sales for our domestic and international stores open at least one year, are as follows:      Constant Currency  12 Weeks   12 Weeks*       Domestic 4.8 %   4.8 %International 11.2 %   3.7 %Total Company 5.5 %   4.7 %* Excludes impacts from fluctuations of foreign exchange rates.             For the quarter, gross profit, as a percentage of sales, was 51.0%, a decrease of 203 basis points versus the prior year. The decrease in gross margin was driven by a 212 basis point non-cash LIFO impact, partially offset by other net margin improvements....

Continue reading

Descartes Announces TSX Acceptance of Normal Course Issuer Bid

WATERLOO, Ontario and ATLANTA, Ga., Dec. 09, 2025 (GLOBE NEWSWIRE) — The Descartes Systems Group Inc. (TSX:DSG) (Nasdaq:DSGX) today announced that the Toronto Stock Exchange (the TSX) has accepted Descartes’ notice to launch a Normal Course Issuer Bid (the Bid). Under the Bid, Descartes may repurchase on the open market, at its discretion during the period commencing on December 11, 2025 and ending on the earlier of December 10, 2026 and the completion of purchases under the Bid, up to 8,568,582 common shares, representing approximately 10% of the “public float” (within the meaning of the rules of the TSX), subject to the normal terms and limitations of such bids. Under TSX rules, the average daily trading volume of the common shares on the TSX during the six months ended November 30, 2025 was approximately 204,706...

Continue reading

Castellum, INC.’s CEO Provides Its Shareholders a Corporate Update

CASTELLUM, INC.’s CEO PROVIDES ITS SHAREHOLDERS A CORPORATE UPDATECastellum, Inc. (NYSE-American: CTM) (the “Company”, “CTM” and “Castellum”), a cybersecurity, electronic warfare, and software services and solutions company focused on the federal government, releases this letter to shareholders from Chief Executive Officer (“CEO”), Glen Ives – www.castellumus.comVIENNA, Va., Dec. 09, 2025 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM) (the “Company”, “CTM” and “Castellum”), a cybersecurity, electronic warfare, and software services and solutions company focused on the federal government, releases this letter to shareholders from Chief Executive Officer (“CEO”), Glen Ives. Dear Fellow Shareholders: As we approach the end of this calendar year, I thought it timely to provide you with a brief update to my July...

Continue reading

Magna Mining Continues to Intersect Copper and Precious Metal Bearing Veins in Multiple Drill Holes at Levack Mine’s R2 Target in Sudbury, Including 25.0% Copper, 34.7 g/t Pt+Pd+Au, and 151 g/t Silver over 0.4 metres

SUDBURY, Ontario, Dec. 09, 2025 (GLOBE NEWSWIRE) — Magna Mining Inc. (TSXV: NICU) (OTCQX: MGMNF) (FSE: 8YD) (“Magna” or the “Company”) is pleased to provide an update on exploration activities and assay results from ongoing exploration at the past-producing Levack Mine, located in the North Range of the Sudbury Basin, northeastern Ontario, Canada (Figure 1). Today’s release incorporates the results from four diamond drill holes which tested the R2 target, with all four holes intersecting multiple veins containing high grade copper (“Cu”) and precious metals, including platinum (“Pt”), palladium (“Pd”), gold (“Au), and silver (“Ag”). Mineralization within the R2 target area has now been intersected over a vertical extent of greater than 200 metres and remains open up-dip towards the No. 3 Footwall Zone and at depth and to the west...

Continue reading

Lands’ End Announces Third Quarter 2025 Results

Increased gross margin approximately 120 basis pointsNet income increased by $5.8 millionAdjusted EBITDA increased by 28% DODGEVILLE, Wis., Dec. 09, 2025 (GLOBE NEWSWIRE) — Lands’ End, Inc. (NASDAQ: LE) today announced financial results for the third quarter ended October 31, 2025. Andrew McLean, Chief Executive Officer, stated: “Our third quarter results underscore the strength of our strategy and disciplined execution. We delivered a 28% increase in Adjusted EBITDA with strong flow through to Adjusted net income, reflecting our focus on profitability and operational efficiency. Our long-term partnership with Delta Air Lines is a powerful example of our leading B2B capabilities, combining product, service and technology to bring solutions to our enterprise clients. In our consumer business, we are reaching a younger, more diverse...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.